PTC Therapeutics, Inc. provided earnings guidance for the year 2022. For the year 2022, the company anticipates total revenues for the full year 2022 to be between $700 and $750 million. The company anticipated net product revenues for the DMD franchise for the full year 2022 to be between $475 and $495 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.01 USD | -1.81% | +15.54% | +19.78% |
04-30 | North American Morning Briefing : More Earnings -2- | DJ |
04-29 | Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.78% | 2.53B | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- PTCT Stock
- News PTC Therapeutics, Inc.
- PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2022